Erschienen in:
01.10.2012 | Letter
A critique of the 2012 ADA/EASD position statement
verfasst von:
H. W. Rodbard, P. S. Jellinger
Erschienen in:
Diabetologia
|
Ausgabe 10/2012
Einloggen, um Zugang zu erhalten
Excerpt
To the Editor: We write as the co-chairs of the task force that developed the American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE) diabetes algorithm. The 2012 position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) for the management of hyperglycaemia in type 2 diabetes [
1] is considerably improved compared with the 2009 statement [
2], and brings the position of the ADA/EASD much closer to the AACE/ACE algorithm [
3]. The AACE/ACE algorithm is still current with only minor modifications: (1) rosiglitazone is no longer available; (2) sitagliptin, exenatide and liraglutide have been approved by the US Food and Drug Administration for use with insulin; (3) weekly exenatide QW is now available; and (4) additional types of dipeptidyl peptidase IV inhibitors have become available. …